It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARGNF’s FA Score shows that 1 FA rating(s) are green whileIMVT’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARGNF’s TA Score shows that 3 TA indicator(s) are bullish while IMVT’s TA Score has 6 bullish TA indicator(s).
ARGNF (@Biotechnology) experienced а 0.00% price change this week, while IMVT (@Biotechnology) price change was +8.19% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +12.63%, and the average quarterly price growth was +68.65%.
IMVT is expected to report earnings on Oct 31, 2025.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
ARGNF | IMVT | ARGNF / IMVT | |
Capitalization | 43.8B | 2.81B | 1,559% |
EBITDA | 690M | -470.69M | -147% |
Gain YTD | 22.634 | -34.921 | -65% |
P/E Ratio | 40.71 | N/A | - |
Revenue | 3.05B | 0 | - |
Total Cash | 3.93B | 599M | 656% |
Total Debt | 43.2M | 98K | 44,082% |
ARGNF | IMVT | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 44 | 70 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 74 Overvalued | 41 Fair valued | |
PROFIT vs RISK RATING 1..100 | 8 | 100 | |
SMR RATING 1..100 | 38 | 98 | |
PRICE GROWTH RATING 1..100 | 40 | 58 | |
P/E GROWTH RATING 1..100 | 79 | 100 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IMVT's Valuation (41) in the null industry is somewhat better than the same rating for ARGNF (74). This means that IMVT’s stock grew somewhat faster than ARGNF’s over the last 12 months.
ARGNF's Profit vs Risk Rating (8) in the null industry is significantly better than the same rating for IMVT (100). This means that ARGNF’s stock grew significantly faster than IMVT’s over the last 12 months.
ARGNF's SMR Rating (38) in the null industry is somewhat better than the same rating for IMVT (98). This means that ARGNF’s stock grew somewhat faster than IMVT’s over the last 12 months.
ARGNF's Price Growth Rating (40) in the null industry is in the same range as IMVT (58). This means that ARGNF’s stock grew similarly to IMVT’s over the last 12 months.
ARGNF's P/E Growth Rating (79) in the null industry is in the same range as IMVT (100). This means that ARGNF’s stock grew similarly to IMVT’s over the last 12 months.
ARGNF | IMVT | |
---|---|---|
RSI ODDS (%) | N/A | N/A |
Stochastic ODDS (%) | 2 days ago42% | 2 days ago71% |
Momentum ODDS (%) | N/A | 2 days ago74% |
MACD ODDS (%) | 2 days ago21% | 2 days ago80% |
TrendWeek ODDS (%) | 2 days ago32% | 2 days ago77% |
TrendMonth ODDS (%) | 2 days ago30% | 2 days ago78% |
Advances ODDS (%) | N/A | 5 days ago75% |
Declines ODDS (%) | N/A | 14 days ago84% |
BollingerBands ODDS (%) | 2 days ago17% | 2 days ago84% |
Aroon ODDS (%) | 2 days ago15% | 2 days ago85% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
CGVEX | 27.65 | 0.15 | +0.55% |
American Funds Global Insight 529-E | |||
ALVIX | 11.12 | N/A | N/A |
American Century Focused Lg Cap Val Inv | |||
GSQTX | 36.02 | N/A | N/A |
Goldman Sachs Small Cap Value Inv | |||
WIESX | 18.09 | N/A | N/A |
Wasatch Emerging Markets Select Instl | |||
RMORX | 26.62 | N/A | N/A |
Victory RS Mid Cap Growth R6 |
A.I.dvisor indicates that over the last year, ARGNF has been loosely correlated with ARGX. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ARGNF jumps, then ARGX could also see price increases.
Ticker / NAME | Correlation To ARGNF | 1D Price Change % | ||
---|---|---|---|---|
ARGNF | 100% | N/A | ||
ARGX - ARGNF | 54% Loosely correlated | +1.04% | ||
MNKD - ARGNF | 30% Poorly correlated | -2.53% | ||
TNXP - ARGNF | 25% Poorly correlated | +2.27% | ||
ROIV - ARGNF | 24% Poorly correlated | -0.46% | ||
IMVT - ARGNF | 24% Poorly correlated | -1.05% | ||
More |